Nxera Pharmas QUVIVIQ (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with…
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy – CORRECTION
April 10, 2026 16:09 ET | Source: Mesoblast Limited Working with Parent…
Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors
Milestones underscore clinical progress and strengthen commercial foundationLOS GATOS, Calif., April 8,…
ENNOVI Secures German Patent Approval for Adhesive-Free Lamination in Battery Cell Contacting Systems
Offering a new, validated CCS design pathway, reducing uncertainty for cautious battery…
QuantPower Receives Official Exchange Approval, Strengthening Its Position in India’s Algo Trading Ecosystem
NOIDA, India, March 13, 2026 /PRNewswire/ -- QuantPower, the AI-enabled algorithmic trading…
Novartis Cosentyx receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL-17A inhibitor approved for this population, and the…
BioAro Secures UAE Approval for AI-Enabled Longevity Bioactives, Setting the Stage for Global Expansion
DUBAI, United Arab Emirates and TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) --…
ZEISS announces NMPA approval in China for powerful ophthalmic microscopes enhancing surgical visualization
ZEISS ARTEVO 750 and ZEISS ARTEVO 850 surgical microscopes provide ophthalmic surgeons…
Press Release: Sanofis Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic…
XED Takes a Major Step Forward as NSE International Exchange Grants In-Principle Approval for India’s First GIFT City IPO
MUMBAI, India, Jan. 24, 2026 /PRNewswire/ -- XED, a globally integrated executive…
